➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
AstraZeneca
Medtronic
Express Scripts
Merck

Last Updated: November 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,323,692

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,323,692 protect, and when does it expire?

Patent 8,323,692 protects GLUMETZA and is included in one NDA.

This patent has twenty-six patent family members in fourteen countries.

Summary for Patent: 8,323,692
Title:Controlled release dosage forms
Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55.degree. C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.
Inventor(s): Frisbee; Steven (Reston, VA)
Assignee: Valeant International Bermuda (Hamilton, BM)
Application Number:12/328,828
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,323,692
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Process;

Drugs Protected by US Patent 8,323,692

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Santarus Inc GLUMETZA metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 021748-002 Jun 3, 2005 AB3 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,323,692

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 536173   Start Trial
Australia 2003211145   Start Trial
Australia 2003211146   Start Trial
Canada 2476201   Start Trial
Canada 2476496   Start Trial
Cyprus 1112517   Start Trial
Denmark 1476138   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Boehringer Ingelheim
Harvard Business School
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.